Graphite Bio begins SCD cell therapy trial; Synthetic Biologics' future rests on VCN acquisition
Graphite Bio has dosed its first sickle cell disease patient with its cell therapy, the Bay Area biotech announced this morning.
In its proof-of-concept CEDAR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
